NCT00036634View on ClinicalTrials.gov

A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

March 31, 2002

Primary Completion Date

February 28, 2003

Study Completion Date

February 28, 2003

Conditions
HIV Infections
Interventions
DRUG

Tenofovir DF

Tenofovir DF tablet administered orally once daily

DRUG

Tenofovir alafenamide

Tenofovir alafenamide tablet(s) administered orally once daily

Trial Locations (3)

10021

Rockefeller University Hospital, New York

60610

Protocare Trials Chicago Center for Clinical Trials, Chicago

94304

Stanford Positive Care Program, Palo Alto

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY

NCT00036634 - A Dose Escalation Study of Tenofovir Alafenamide in Treatment-Naive Patients | Biotech Hunter | Biotech Hunter